» Articles » PMID: 24560446

Validation of a Prognostic Multi-gene Signature in High-risk Neuroblastoma Using the High Throughput Digital NanoString NCounter™ System

Abstract

Microarray-based molecular signatures have not been widely integrated into neuroblastoma diagnostic classification systems due to the complexities of the assay and requirement for high-quality RNA. New digital technologies that accurately quantify gene expression using RNA isolated from formalin-fixed paraffin embedded (FFPE) tissues are now available. In this study, we describe the first use of a high-throughput digital system to assay the expression of genes in an "ultra-high risk" microarray classifier in FFPE high-risk neuroblastoma tumors. Customized probes corresponding to the 42 genes in a published multi-gene neuroblastoma signature were hybridized to RNA isolated from 107 FFPE high-risk neuroblastoma samples using the NanoString nCounter™ Analysis System. For classification of each patient, the Pearson's correlation coefficient was calculated between the standardized nCounter™ data and the molecular signature from the microarray data. We demonstrate that the nCounter™ 42-gene panel sub-stratified the high-risk cohort into two subsets with statistically significantly different overall survival (p = 0.0027) and event-free survival (p = 0.028). In contrast, none of the established prognostic risk markers (age, stage, tumor histology, MYCN status, and ploidy) were significantly associated with survival. We conclude that the nCounter™ System can reproducibly quantify expression levels of signature genes in FFPE tumor samples. Validation of this microarray signature in our high-risk patient cohort using a completely different technology emphasizes the prognostic relevance of this classifier. Prospective studies testing the prognostic value of molecular signatures in high-risk neuroblastoma patients using FFPE tumor samples and the nCounter™ System are warranted.

Citing Articles

Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care.

Alontaga A, Cano P, Ozakinci H, Puskas J, Stewart P, Welsh E J Mol Diagn. 2024; 26(8):685-699.

PMID: 38777037 PMC: 11299514. DOI: 10.1016/j.jmoldx.2024.04.005.


Development and validation of a 21-gene prognostic signature in neuroblastoma.

Gupta M, Kannappan S, Jain M, Douglass D, Shah R, Bose P Sci Rep. 2023; 13(1):12526.

PMID: 37532697 PMC: 10397261. DOI: 10.1038/s41598-023-37714-9.


Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.

Melaiu O, Chierici M, Lucarini V, Jurman G, Conti L, De Vito R Nat Commun. 2020; 11(1):5992.

PMID: 33239635 PMC: 7689423. DOI: 10.1038/s41467-020-19781-y.


Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies as the strongest independent predictor of recurrence.

Yan W, Jamal M, Tan S, Song Y, Young D, Chen Y Oncotarget. 2019; 10(60):6466-6483.

PMID: 31741711 PMC: 6849651. DOI: 10.18632/oncotarget.27294.


Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.

McQuerry J, Jenkins D, Yost S, Zhang Y, Schmolze D, Johnson W BMC Cancer. 2019; 19(1):881.

PMID: 31488082 PMC: 6727561. DOI: 10.1186/s12885-019-6052-z.


References
1.
Fernandez P, Solenthaler M, Spertini O, Quarroz S, Rovo A, Lovey P . Using digital RNA counting and flow cytometry to compare mRNA with protein expression in acute leukemias. PLoS One. 2012; 7(11):e49010. PMC: 3494663. DOI: 10.1371/journal.pone.0049010. View

2.
Garcia I, Mayol G, Rios J, Domenech G, Cheung N, Oberthuer A . A three-gene expression signature model for risk stratification of patients with neuroblastoma. Clin Cancer Res. 2012; 18(7):2012-23. PMC: 4240975. DOI: 10.1158/1078-0432.CCR-11-2483. View

3.
Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View

4.
Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View

5.
Santana V, Furman W, Billups C, Hoffer F, Davidoff A, Houghton P . Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol. 2005; 23(18):4039-47. DOI: 10.1200/JCO.2005.02.097. View